Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 1 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 1 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER vs INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Peritoneal dialysis solution with dextrose as osmotic agent; dextrose creates osmotic gradient across peritoneal membrane to remove excess fluid and uremic toxins.
Inpersol-LC/LM with dextrose 1.5% is a peritoneal dialysis solution. The mechanism involves instillation into the peritoneal cavity, where dextrose creates an osmotic gradient that drives ultrafiltration of fluid and removal of uremic toxins (e.g., urea, creatinine) across the peritoneal membrane. The low calcium (LC) and low magnesium (LM) formulation helps prevent hypercalcemia and hypermagnesemia.
Intraperitoneal administration via automated peritoneal dialysis (APD) or continuous ambulatory peritoneal dialysis (CAPD); typical adult dose is 2-3 liters per exchange, 4-5 exchanges per day (CAPD) or 8-12 liters total volume per night (APD).
Intraperitoneal administration: For continuous ambulatory peritoneal dialysis (CAPD), instill 2 liters of 1.5% dextrose solution into the peritoneal cavity via a permanent indwelling catheter. Exchange 4 times per day (every 6 hours) with a dwell time of 4-6 hours. For automated peritoneal dialysis (APD), typical regimen includes 2 liters per cycle with 4-5 cycles overnight and a daytime dwell.
None Documented
None Documented
Not applicable: Dextrose absorbed from peritoneal dialysate has a half-life similar to IV glucose (approx. 1-2 hours), but as a dialysis solution, the concept of terminal elimination half-life is not defined for the non-absorbed components. Clinical context: continuous intraperitoneal administration.
Not applicable via systemic absorption; glucose absorbed from dialysate exhibits a terminal half-life of 1.5–2 hours in plasma, reflecting rapid cellular uptake and metabolism.
Peritoneal dialysis fluid: DIALYTE components (electrolytes, dextrose) are not systemically absorbed in clinically significant amounts; dextrose is partially absorbed across the peritoneum and metabolized. Renal and biliary excretion are not relevant as this is a topical intraperitoneal solution. Elimination of absorbed dextrose follows glucose metabolism (oxidation, storage).
Renal: negligible; primarily eliminated via peritoneal dialysis (dialysate outflow). Biliary/fecal: <1%.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution